Background: Metabolic syndrome (MetS) is a risk factor for development of cancer. Because aberrant lipid metabolism is a pathogenic feature of chronic lymphocytic leukemia (CLL), our objective was to determine if CLL patients have a higher prevalence of MetS preceding diagnosis and to determine the impact of lipid-lowering medications on survival. Methods: We conducted a population-based case-control study in Ontario, Canada, using administrative databases of adults age 66 years and older to compare the prevalence of MetS preceding CLL with age-and sex-matched control subjects. Logistic regression was used to study the association between MetS and its components to CLL. The Kaplan-Meier method and Cox Regression were used to investigate survival. All statistical tests were two-sided. Results: We identified 2124 persons with CLL and 7935 control subjects from January 1, 2000, to December 31, 2005, with follow-up until March 31, 2014, three years from the date of last contact with the health care system, or death. The mean age was 75.6 years, 20.2% had diabetes, 35.8% had hypertension, and 17.6% had dyslipidemia. In multivariable analysis, dyslipidemia (odds ratio [OR] ¼ 1.26, 95% confidence interval [CI] ¼ 1.11 to 1.44, P < .001) and hypertension (OR ¼ 1.12, 95% CI ¼ 1.01 to 1.25, P ¼ .03) were associated with the development of CLL, whereas MetS and diabetes were not. Lipid-lowering medication was associated with a statistically significant improved survival in patients with CLL (HR ¼ 0.53, 95% CI ¼ 0.47 to 0.61, P < .001). Conclusions: We demonstrate a higher prevalence of dyslipidemia preceding a diagnosis of CLL compared with control subjects, supporting preclinical data. Lipid-lowering medications appear to confer a survival advantage in CLL. Prospective studies are needed to confirm these results and test their potential as therapeutic applications.
plasma of CLL patients contains high levels of free fatty acids (FFAs) and oleoylethanolamide, a lipolytic factor that releases FFAs from adipocytes (9) . Taken together, these observations suggest that aberrant lipid metabolism is a pathogenic mechanism in CLL.
The metabolic syndrome (MetS) consists of five components: abdominal obesity, raised triglycerides, reduced HDL cholesterol, raised blood pressure, and elevated fasting plasma glucose (13, 14) . These risk factors are independently associated with type II diabetes mellitus and cardiovascular disease (15) . Insulin resistance explains many of the manifestations of MetS (15) , including an increase in lipolysis and free fatty acid release into the bloodstream (16) . MetS affects up to 23% of the American population (17) and increases in prevalence with age (18) . Given the apparent dependence of CLL cells on lipids, MetS may also be a risk factor for the development of CLL. However, very little clinical evidence is available to assess this relationship.
The purpose of this study was to explore the association between three components of MetS (dyslipidemia, diabetes, and hypertension) with the development of CLL. Secondarily, we also sought to examine whether antidyslipidemic medications had an impact on the survival of patients with CLL.
Methods

Study Design and Cohort Selection
This is a population-based, case-control study of patients age 66 years and older diagnosed with CLL in Ontario, Canada, from January 1, 2000, to December 31, 2005 , and followed until March 31, 2014, three years from date of last contact with the health care system, or death. To avoid incomplete medication records, we excluded patients during their first year of Ontario Drug Benefit program (ODB) eligibility. ODB is a provincial program that provides prescription medication coverage to Ontario residents age 65 years and older. We also excluded patient cases if they did not have a valid provincial health insurance number, if they were nonresidents of Ontario, or if they were diagnosed with CLL at death or autopsy. Control subjects without CLL were randomly selected from the general Ontario population and matched to CLL cases on birth year and sex. A maximum of five control subjects were matched to each CLL case, and control subjects were sampled without replacement. Given that five unique matched control subjects could not be identified for each CLL case, a sensitivity analysis was performed with the random selection of one control subject per CLL case. This was compared with the analysis with a maximum of five matched control subjects per CLL case. A subcohort of CLL cases age 71 years and older was used to assess survival of patients diagnosed with CLL. The increased restriction on patient age was applied in order to ensure at least five years of prescription history was available for each patient.
Data Sources
The Ontario Cancer Registry (OCR) was used to identify CLL cases. The OCR is a population-based cancer registry that captures approximately 95% of all provincial cancer diagnoses since 1964 (19) . CLL cases were required to have both the International Classification of Diseases, Ninth Revision (ICD-9), code for CLL (204.1) and the ICD for Oncology (ICD-O-3) code for CLL histology (9823/3). CLL cases from the OCR were linked using coded patient identifiers from provincial health card numbers to administrative databases (Supplementary Methods, available online). These data sets were linked and analyzed at the Institute for Clinical Evaluative Sciences. Ethical approval for this study was obtained from the Research Ethics Board of the Sunnybrook Health Sciences Centre, Toronto. Patient informed consent was waived as the data was deidentified and anonymized before given to the investigators.
Variable Definitions
The presence of diabetes was identified using the Ontario Diabetes Database (ODD) or if patients had receipt of prescriptions for insulin or oral antihyperglycemic agents in ODB in the 10 years prior to a CLL diagnosis. Hypertension was identified using the Ontario Hypertension Database (OHD) in the 10 years prior to a CLL diagnosis. Patients were not labeled as hypertensive if they only had prescriptions for antihypertensive agents and were not in the OHD, given that these drugs may have been prescribed for other indications (eg, post-myocardial infarction). Dyslipidemia was defined as patients who had either two dyslipidemia diagnosis codes identified from Ontario Health Insurance Plan (OHIP) within two years of each other or one dyslipidemia diagnosis code from the Discharge Abstract Database/Same Day Surgery (DAD/SDS) in the 10 years prior to CLL diagnosis. As a sensitivity analysis, we also compared outcomes with two alternate definitions of dyslipidemia: 1) prescriptions for antidyslipidemic agents and 2) any dyslipidemia diagnosis code identified either from OHIP or DAD/SDS. All prescription agents were identified using drug identification numbers in the ODB and included antidyslipidemics (eg, statins, fibrates), oral hypoglycemics (eg, sulfonylureas, biguanides), and insulin. MetS was defined as the coexistence of diabetes, hypertension, and dyslipidemia. We also performed a sensitivity analysis excluding CLL patients with incident chronic disease (diabetes, hypertension, dyslipidemia) within six months of CLL diagnosis to ensure that the diagnosis of CLL did not lead to an increase in the diagnosis of the other conditions of interest. Physician visits (general practitioner/family physician or specialists) were recorded from 10 years prior to CLL diagnosis or date of first OHIP eligibility (whichever occurred first) until CLL diagnosis and were recorded as the average number of visits per year. Physician visits after diagnosis were recorded from the date of diagnosis until the end of follow-up and were recorded as an average number of visits per year or the absolute number of visits for those patients surviving less than one year. The primary outcome was the association of MetS and its components to the subsequent development of CLL. The impact of antidyslipidemic agents before and/or after the diagnosis of CLL (absolute/total duration) on overall survival (OS) in patients with CLL was a secondary endpoint.
Comorbid disease burden was measured utilizing Johns Hopkins Adjusted Clinical Groups (ACG) System, a case-mix system used to score comorbidity on the basis of clinical similarity, chronicity, likelihood of requiring specialty care, and disability. The system uses diagnostic information obtained from administrative databases to describe and predict the use of health care resources (20). ICD-9 and ICD-10-CA codes and OHIP diagnosis codes were used to compute the Aggregated Diagnosis Groups (ADGs) in the year prior to a CLL diagnosis, where a larger number of ADGs represents a greater comorbidity burden. Diagnoses related to diabetes, dyslipidemia, hypertension, and CLL were excluded in the calculation of patient ADGs to reduce the risk of modeling duplicated covariates because components of MetS were, in part, identified using patient diagnoses in administrative data.
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Baseline characteristics of the CLL cases and control subjects were generated, and the differences between groups were compared using X 2 tests (categorical variables) or two sample pooledvariance t tests (continuous variables). Logistic regression modeling was used to examine the association of CLL and MetS components. Both crude and adjusted odds ratios (ORs) were computed. To minimize colinearity in the model, variables in the multivariable regression were limited to the exposure of interest (components of metabolic syndrome separately and together), rural address, number of ADGs, and income quintile. Propensity score for the prescription of antidyslipidemic agents was also calculated for the entire cohort and included the following variables: sex, age, number of ADGs, rurality, income quintile, history of MI, history of stroke/TIA, average number of physician visits per year prior to CLL diagnosis, and the presence of hypertension, diabetes, and dyslipidemia. In the survival subanalysis, the cohort of CLL patients age 71 years and older was analyzed. OS was measured from the date of CLL diagnosis to the date of death (allcause), end of the study window, March 31, 2014 (censored), or three years from date of last contact with the health care system (censored). Crude and adjusted hazard ratios were obtained using Cox Proportional Hazards models, and survival curves were generated using the Kaplan-Meier method, stratified by covariates. The assumption of proportionality was verified by assessing whether the exposure hazard ratio varied over time. This was carried out by including an interaction between the covariates and survival time, in conjunction with reviewing Kaplan-Meier figures for categorical effects. Final models were adjusted for sex, age, number of ADGs, rurality, income quintile, hypertension, diabetes, dyslipidemia, dyslipidemia treatment, metformin treatment, history of MI, history of stroke/TIA, and propensity score for dyslipidemia treatment and for the time-dependent effect of average number of physician visits per year after CLL diagnosis. Statistical tests were two-sided, using an alpha level of .05. All statistical analyses were performed using SAS Enterprise Guide version 6.1 (2013, SAS Institute Inc., Cary, NC).
Results
Baseline Characteristics
Between 2000 and 2005, 2124 patients were diagnosed with CLL in Ontario, Canada, and 7935 age-and sex-matched patients without CLL were used as control subjects. This excluded approximately 40% of those diagnosed with CLL at less than 66 years of age. Of those with CLL, 56.0% had five matched control subjects and 71.2% had least three matched control subjects. Baseline demographic and clinical characteristics are presented in Table 1 . Overall, the median age was 75.6 years, 20.2% had diabetes, 35.8% had hypertension, and 17.6% had dyslipidemia. There was a statistically significant but clinically unimportant interaction between statins and age; younger patients were more likely to use statins (mean age ¼ 75.7 years no statin vs 75.1 years statin, P < .001). The adjusted analysis also included rurality, ADGs (0 to 5 and 6 to 10 vs 11 or more), and income quintile (each quintile compared with the highest income quintile). Rurality was not statistically significantly associated with CLL, whereas higher comorbidities (ADGs) and income quintiles were statistically significantly associated with CLL (data not shown). In the multivariable model including the three components of MetS separately, dyslipidemia (OR ¼ 1.25, 95% CI ¼ 1.10 to 1.42, P < .001) was associated with the development of CLL, whereas hypertension (OR ¼ 1.10, 95% CI ¼ 0.99 to 1.23, P ¼ .07) and diabetes (OR ¼ 1.06, 95% CI ¼ 0.94 to 1.20, P ¼ .35) were not (data not shown). In our sensitivity analysis excluding CLL patients with incident chronic disease (diabetes, hypertension, dyslipidemia) within six months of CLL diagnosis, dyslipidemia (adjusted OR ¼ 1.28, 95% CI ¼ 1.12 to 1.46, P < .001) remained statistically significantly associated with the development of CLL, whereas hypertension did not (adjusted OR ¼ 1.07, 95% CI ¼ 0.96 to 1.20, P < 0.21). In the multivariable model including the three components of MetS separately, dyslipidemia retained its statistical significance (OR ¼ 1.27, 95% CI ¼ 1.12 to 1.46, P < .001) for this sensitivity analysis (data not shown).
Predictors of CLL Development
We also conducted a second sensitivity analysis by randomly selecting one control subject for each CLL case in the primary sensitivity analysis. We again found that hypertension was not statistically significantly predictive of the development of CLL (adjusted OR ¼ 1.08, 95% CI ¼ 0.94 to 1.24, P ¼ .26; data not shown), whereas it was statistically significantly predictive in the other analysis (see Table 2 ). Dyslipidemia remained statistically related using both methods of patient case/control subject. Table 3 demonstrates the crude and adjusted mortality analysis for patients with CLL. Treatment with an antidyslipidemic agent was protective for survival (adjusted HR ¼ 0.53, 95% CI ¼ 0.47 to 0.61, P < .001), as were statins (modeled separately) (adjusted HR ¼ 0.53, 95% CI ¼ 0.46 to 0.60, P < .001), whereas the presence of dyslipidemia had no effect on survival on multivariable analysis (adjusted HR ¼ 0.79, 95% CI ¼ 0.28 to 2.19, P ¼ .65). In addition, male gender, older age, and greater number of physician visits per year since CLL diagnosis were associated with a statistically significantly worse overall survival, whereas history of stroke/MI, metformin use, and propensity score for dyslipidemia treatment were not (see Table 3 ). However, when removing number of physician visits per year from the model, both stroke/TIA (adjusted HR ¼ 1.32, 95% CI ¼ 1.01 to 1.66, P ¼ 0.02) and MI (adjusted HR ¼ 1.70, 95% CI ¼ 1.11 to 2.63, P ¼ .02) were statistically significantly associated with a worse overall survival (data not shown).
Predictors of Survival in CLL Patients
Overall Survival in CLL Patients
The median OS of the entire CLL cohort was 6.5 years (95% CI ¼ 6.2 to 6.8), with a median follow-up of 10.7 years (95% CI ¼ 10.5 to 10.9; data not shown). When restricted to CLL patients age 71 years and older, the median OS in those without dyslipidemia was 5.3 years (95% CI ¼ 4.9 to 5.7) vs 7.4 years in those with dyslipidemia (95% CI ¼ 6.7 to 8.5, P < .001) ( Figure 1A) , although on multivariable analysis dyslipidemia was not predictive of survival. A statistically significantly longer OS was seen in those without diabetes (6.1 years, 95% CI ¼ 5.5 to 6.5, vs 4.8 years, 95% CI ¼ 4.2 to 5.4, P ¼ .01) ( Figure 1B ) but not hypertension (5.6 years, 95% CI ¼ 5.1 to 6.2, vs 5.8 years, 95% CI ¼ 5.2 to 6.5, P ¼ .53) ( Figure 1C ). In addition, patients receiving antidyslipidemic agents before or after CLL diagnosis had an improved median OS (7.8 years, 95% CI ¼ 7.3 to 8.4, vs 4.1 years, 95% CI ¼ 3.7 to 4.5, P < .001) (Figure 2A ), as did those receiving statins ( Figure 2B ). There was also an improved OS for female patients, those with TIA ¼ transient ischemic attack. †Modeled separately from dyslipidemia treatment ever. ‡Average number of physician visits per year after CLL diagnosis and its interaction with time were both statistically significantly associated with a worse overall survival. Figure 1 . Kaplan-Meier curves for overall survival in chronic lymphocytic leukemia patients based on dyslipidemia status (A), diabetes status (B), and hypertension status (C). P values were determined using a two-sided log-rank test.
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a lower comorbid disease burden, and younger patients ( Figure  3 ). There were statistically significantly more deaths due to cardiovascular disease in those receiving dyslipidemia treatment (Table 4) .
Discussion
This population-based case-control study of CLL patients in Ontario, Canada, demonstrates a higher prevalence of dyslipidemia (22.2% vs 16.3%), diabetes mellitus (22.4% vs 19.6%), and hypertension (39.0% vs 34.9%) in patients who develop CLL compared with matched control subjects. However, on multivariable analysis the association of MetS and CLL appears to be driven primarily by dyslipidemia and remains statistically significant when varying the number of control subjects per patient case and excluding CLL patients with incident chronic disease (diabetes, hypertension, dyslipidemia) within six months of CLL diagnosis, signifying that these results are robust. In addition, both lipid-lowering medications and statins alone appear to confer a survival advantage in CLL (7.8 vs 4.1 years), which cannot be explained by a reduction in death due to cardiovascular disease as there were statistically significantly more deaths from cardiovascular causes in those receiving dyslipidemia treatment.
A systematic review of 38 940 patients demonstrated a statistically significant association between MetS and common cancers such as hepatic, colorectal, bladder, endometrial, pancreatic, and postmenopausal breast (21) . However, none of the data sets included patients with hematologic malignancies. Studies in colorectal cancer have shown a reduction in cancerspecific mortality with statin use (22, 23) , although these associations have not been validated when adjustments for potential confounders including lifestyle factors, health-related behavior comorbidities, and concomitant medications were performed (24) .
A recent retrospective cohort study demonstrated a high incidence (75%) of dyslipidemia defined by statin use or elevated nonfasting low-density lipoprotein cholesterol levels and a longer time to first treatment in patients receiving statins (excluding those with 17p deletions). Time to first treatment was also longer if patients were prescribed statins after a CLL diagnosis. However, this was a single-center study and did not include information on the other components of MetS (25) . In contrast, an observational cohort study from the Mayo Clinic did not find an impact of statins to time of initial Figure 2 . Kaplan-Meier curves for overall survival in chronic lymphocytic leukemia patients based on antidyslipidemic agent use ever (A) and statin use (B). P values were determined using a two-sided log-rank test.
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therapy and OS in patients with CLL, although they only included patients with Rai stage 0 disease (26) . Similarly, a single-center study found no statistically significant difference in statin use and treatment-free survival or overall survival, although the median follow-up for patients on statins was short (2.4 years) (27) . These studies included predictive markers such as stage or cytogenetics that were unavailable in our study. However, strengths of our population-based study compared with these include the large sample size, longer followup, and consideration of other components of metabolic Figure 3 . Kaplan-Meier curves for overall survival in chronic lymphocytic leukemia patients based on sex (A), comorbidity (Aggregated Diagnosis Groups) status (B), and age (C). P values were determined using a two-sided log-rank test. ADG ¼ Aggregated Diagnosis Groups (higher number represents greater comorbid disease burden).
ARTICLE syndrome (hypertension, diabetes) and the impact of comorbid diseases.
The European Prospective Investigation into Cancer and Nutrition is a multicenter prospective cohort study investigating environmental factors such as nutritional status and the risk of cancer (28) . Overall, there was no statistically significant association between diabetes (self-reported) and the risk of cancer in the non-Hodgkin's lymphoma and multiple myeloma cohorts. However, there was a positive association between diabetes and B-CLL in men but not women. To our knowledge, our study is the first population-based study to report on MetS and its components specifically in CLL.
There are several limitations to our study. When the sensitivity analysis of 1:1 random control subjects was performed, hypertension was no longer statistically significantly related to the diagnosis of CLL. In addition, when excluding CLL patients with incident chronic disease (diabetes, hypertension, dyslipidemia) within six months of CLL diagnosis, hypertension was no longer statistically significantly associated with CLL. We believe this may simply be because of the small effect size of hypertension. Fortunately, in both sensitivity analyses, a statistically significant association of dyslipidemia with CLL remained, demonstrating that this association is robust. In addition, because of ODB eligibility, we excluded approximately 40% of those diagnosed with CLL at less than 66 years of age. Given that the median age of CLL diagnosis is 72 years (3,4), we still believe that our results are applicable to the majority of patients.
The OS in our CLL cohort was lower than expected (6.5 years) compared with more than 10 years in other series (29, 30) . Survival is dependent on many disease-related factors including stage, lymphocyte-doubling time (31), beta-2-microglobulin levels (32), immunoglobulin variable region heavy chain gene (IgVH) mutations (33), chromosomal abnormalities (eg, 17p deletions) (34) , and molecular aberrations (35, 36) . In our populationbased study, granular disease characteristics were unavailable; therefore we were unable to account for this shorter survival or adjust for it in our analyses. It is possible that the administrative database sources of our patient cases may have skewed patient characteristics toward more advanced or symptomatic disease. The OCR contains cancer diagnoses garnered from a number of sources, including hospital admission and discharge diagnoses, tertiary care provincial cancer centers, and chemotherapy treatment records. However, early-stage CLL may not have been included in these patient cases because peripheral blood flow cytometry reports demonstrating the characteristic CLL immunophenotype-the method most commonly used to investigate lymphocytosis-and even bone marrow biopsies are not routinely reported to the Ontario Cancer Registry. A series from the Mayo Clinic reported an OS of 9.5 years in patients older than age 55 years, although 56.5% and 37.3% of these patients were Rai stage 0 (low) and 1-2 (intermediate), respectively (37) . In contrast, a series from the MD Anderson Cancer Center reported an OS of 5.3 to 7.0 years for Rai stage 3-4 (high) disease (29) , highlighting the influence of disease stage on survival. The OS in our cohort is likely representative of patients with more advanced-stage disease at entry. In addition, we were unable to determine medication adherence, smoking status, duration of dyslipidemia treatment, baseline lipid status, and HbA1c measurements, though it is unknown if these factors would impact the natural history of CLL.
The mechanism explaining the link between dyslipidemia and CLL and the impact of lipid-lowering medications on disease course has not been elucidated. One possibility is that dyslipidemias are low-grade inflammatory diseases and inflammatory factors such as interleukin-6 (38) are known to promote the proliferation of CLL cells. Uptake of lipoproteins and their contents may alter signaling machinery, such as lipid rafts, and enhance proliferative responses of CLL cells to inflammatory factors (39) . These effects would be reversed by statins.
Our population-based study demonstrates an association between dyslipidemia and the subsequent development of CLL. We also demonstrate improved survival in those CLL patients receiving lipid-lowering medications. Further work is required to explore possible underlying mechanisms, and ultimately prospective studies are needed to confirm these results and test their potential application as therapeutic agents.
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